

Eveline Wesby van Swaay

Eveline has 13 years industry experience (AstraZeneca, OrionPharma) . She is responsible for patient safety in a rheumatoid arthritis programme and is a strong advocate to optimize communication to protect patients . Eveline is member of an internal advisory board for genotoxicity, and led an optimisation programme of the clinical/non-clinical interface . She also helped build a model for outsourcing clinical pharmacology studies .

During her time at Orion, she set up expert review boards for a heart failure programme, and wrote a screenplay for a mock Ethics Committee discussing genetic testing at an international IRB conference .

Eveline was in clinical practice for 16 years as a consultant paediatrician/geneticist . She was one of the initiators of a novel multidisciplinary specialist service for the care and counselling of children born with complicated heart defects . Her research work included cystic fibrosis and teratogenicity of anti-epileptics . She was medical advisor for a patient organisation (Prader-Willie) and member of the Dutch skeletal dysplasia committee .